Summary of findings for the main comparison. Summary of survival outcomes.
IP component therapy compared with IV therapy for initial management of primary epithelial ovarian cancer | ||||
Patient or population: Women with newly diagnosed epithelial ovarian cancer Settings: Hospital setting Intervention: Intraperitoneal component therapy Comparison: Intravenous therapy | ||||
Outcomes | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments |
Overall survival | HR 0.81 (0.72 to 0.90) |
2026 women (8 trials) |
⊕⊕⊕⊕ high | Homogeneous data. When only the six high quality trials were considered HR = 0.80 (0.72 to 0.90) . |
Progression‐free survival | HR 0.78 (0.70 to 0.86) | 1311 women (5 trials) | ⊕⊕⊕⊕ high | Homogeneous data. |
CI: Confidence interval; HR: Hazard Ratio | ||||
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. |